Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

open", "step towards", "planned", "believes", "expected", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation, the Company's need for additional capital, which may not be available in a timely manner or at all and which, if not obtained, will have a material adverse impact on the Company and its ability to continue; uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; uncertainty whether planned clinical trials will occur as expected or whether such trials, as well as the ongoing clinical trial in Sweden and Germany, will be successful; product liability and insurance risks; research and development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, including its latest Annual Information Form, at http://www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, opinio
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... SEATTLE , July 11, 2014  Researchers ... navigate three-dimensional images. The new technology, called Virtual ... of small structures like neurons and synapses using ... Finger,s unique technology makes 3D imaging studies orders ... resources at an unprecedented level across many areas ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Women ... have access to an additional family planning option. ... to contraception at all levels of the health ... formulation of a widely used contraceptive—Pfizer’s Depo-Provera® (depot ... Burkina Faso is the first of four African ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... Report Represents Major Step in Cancer Genome Research, ... a Beckman Coulter company, announced today that its,Genomic ... released study from,Johns Hopkins Kimmel Cancer Center. The ... the discovery of 200 genes linked to breast ...
... Biosciences Inc. announces the,launch of its SurgiMend(TM) Collagen ... 510(k) clearance from the U.S. Food and Drug,Administration ... and,reconstructive surgery, including breast reconstruction, and for tendon,augmentation, ... and,muscle flap reinforcement indications. "SurgiMend has been ...
... to empower transplant patients ... and ... US,Inc. (Pink Sheets: ALPMF), a leader in the field of ... organization, announced a collaborative partnership to jointly,develop further materials for ...
Cached Biology Technology:Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers 2Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers 3TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... research findings from the Centre for Permafrost (CENPERM) at ... of Copenhagen, document that permafrost during thawing may result ... atmosphere and that the future water content in the ... thawing. The findings may lead to more accurate climate ...
... Hanover, N.H.The ability to pay attention to relevant information ... the ability to focus and filter out "noise," we ... study of attention in the brain, the cellular mechanisms ... mystery... until now., In a study appearing in the ...
... a new way to join materials together using ultrasound. Ultrasound ... normally used to smash particles apart in water. In a ... Jake Barralet, from the faculties of Dentistry and Medicine, found ... bond together into strong agglomerates, about the size of grains ...
Cached Biology News:New knowledge about permafrost improving climate models 2Quantum of sonics: Bonded, not stirred 2
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
HyPro 20 system for slide hybridization. 20 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: